NeoGenomics appoints David Perez to board, Warren Stone as clinical services president

NEOGENOMICS INC

David B. Perez appointed to Board effective Nov 3, 2022; term until 2023 annual meeting.
Warren Stone appointed President, Clinical Services Division effective Nov 21, 2022, replacing Dr. David Sholehvar.
Stone's compensation: $525K base, 50% target bonus, $1M annual equity, $350K sign-on cash, $2M sign-on equity, $250K relocation.
Perez is former Terumo BCT CEO; brings 40 years of global executive leadership experience in medical devices and healthcare.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David B. Perez

Director

NEO · NEOGENOMICS INC

Effective: 2022-11-03
Filed: November 7, 2022, 6:59 PM ET

Effective November 3, 2022, the Board of Directors (the “Board”) of NeoGenomics, Inc., a Nevada corporation (the “Company”), appointed David B. Perez to serve as a member of the Board.

Departed

Dr. David Sholehvar

President, Clinical Services Division

NEO · NEOGENOMICS INC

Effective: 2022-11-04
Successor: Warren Stone
Filed: November 7, 2022, 6:59 PM ET

The Company's former President, Clinical Services Division, Dr. David Sholehvar’s last day at the Company was November 4, 2022

Appointed

Warren Stone

President, Clinical Services Division

NEO · NEOGENOMICS INC

Effective: 2022-11-21
Filed: November 7, 2022, 6:59 PM ET

On November 2, 2022, the Company appointed Warren Stone, age 50, President, Clinical Services Division of the Company, effective November 21, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David B. Perez was appointed as Director at NEOGENOMICS INC.

Action: appointed
Role: Director

Exact text from the filing

Effective November 3, 2022, the Board of Directors (the “Board”) of NeoGenomics, Inc., a Nevada corporation (the “Company”), appointed David B. Perez to serve as a member of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. David Sholehvar departed as President, Clinical Services Division at NEOGENOMICS INC.

Action: departed
Role: President, Clinical Services Division

Exact text from the filing

The Company's former President, Clinical Services Division, Dr. David Sholehvar’s last day at the Company was November 4, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Warren Stone was appointed as President, Clinical Services Division at NEOGENOMICS INC.

Action: appointed
Role: President, Clinical Services Division

Exact text from the filing

On November 2, 2022, the Company appointed Warren Stone, age 50, President, Clinical Services Division of the Company, effective November 21, 2022

View on SEC.gov

NEOGENOMICS INC filing history →

Source: SEC EDGAR

accession 0001077183-22-000163

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.